October 11, 2005 14:11 ET

Nymox Adds European Sales Agreements For Company's Proprietary Unique AlzheimAlert™ Test; Nymox AlzheimAlert™ Test Available With CLIA Certification in U.S. and With CE Mark in Europe

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 11, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) continues to make major progress in the global marketing strategy for the Company's unique urine testing technology for Alzheimer's disease (AD). The Company now has attained U.S. federal and state CLIA approval in the U.S., and the CE Mark in Europe. The Company recently announced distribution and marketing agreements for Italy with Alifax S.p.A., for Spain with Brainpharma S.L., for the Czech Republic with KlinLab Inc., and for Greece with B. Carivitis S.A.

Brian Doyle, Global Sales Manager of Nymox said, "There is a large global market for this one-of-a-kind patented technology. In Europe, Japan, and the U.S. there are over 100 million persons age 65 and over".

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

AlzheimAlert™ is certified as a laboratory testing service in the U.S. through the Company's CLIA-certified clinical reference laboratory in Maywood, New Jersey. A kit version of AlzheimAlert™ is also available for sale in Europe as a result of its certification with a CE Mark, making the test kit eligible for sale in the European Union.

There is an extensive scientific and medical literature on the brain protein (neural thread protein or NTP) detected by the Company's Alzheimer test and on its usefulness as an aid to the diagnosis of Alzheimer's disease. Publications include, for example, Journal of Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3: 345-353); Cellular and Molecular Life Sciences (2003; 60: 2679-91) and (2001; 58: 844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002; 7:d989-96); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX